Company: Kahr Medical
Job title: Chief Executive Officer
Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology, heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. CEO of KAHR Medical, a privately-held biotechnology company developing a novel drug platform based on, bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications. Prior to joining KAHR Medical, served as Chief Development Officer at Cellect Biotechnology (NASDAQ: APOP) and as Senior Director of Oncology at BioLineRx (NASDAQ: BLRX). Holds a Ph.D. in Molecular Genetics and Biochemistry from the Tel-Aviv University and was a post-doctoral fellow at Genentech, a leading biotechnology company, member of the Roche Group.
DSP107, a Novel Immunotherapeutic Targeting both Innate & Adaptive Immunity 11:30 am
• Outline Dual Signaling Protein (DSP) platform technology • Learn about the DSP107 mechanism of action targeting both CD47 whilst simultaneously activating the immune cells via the 41BBL pathway • Discuss CD47 targeting with a differentiated PK and safety profileRead more
day: Day One